Nasdaq · CIK 0000715446
ANIX Anixa Biosciences Inc
Insider trading from SEC Form 4. Last filing 13 d ago. Close $2.90 on Oct 9, 2026, +23% from the 52-week low and -44% from the high.
Anixa Biosciences Inc (ANIX) has 36 SEC Form 4 filings on file from 5 insiders, the latest filed on Sep 30, 2026. In the last 90 days insiders made 7 open-market buys worth $230k and 0 open-market sells worth $0, net +$230k.
23 open-market trades have been scored at ANIX. The newest: Michael Catelani (President, COO, & CFO) bought $16k of stock on Sep 30, 2026, filed Sep 30, 2026, scored 40 (moderate). The largest of the 23 shown: Lewis H Titterton jr (director) bought $132k on Sep 23, 2026, scored 46 (moderate). 4 insiders bought within 14 days of each other around Sep 30, 2026.
ANIX closed at $2.90 on Oct 9, 2026, 23% above its 52-week low and 44% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Anixa Biosciences Inc, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Michael Catelani President, COO, & CFO buy | $16k 5,500 shares | +12% | - | |
| 30Weak | Arnold M Baskies director buy | $14k 5,000 shares | +4% | - | |
| 45Moderate | Amit Kumar Chief Executive Officer buy | $19k 7,000 shares | +1% | - | |
| 46Moderate | Lewis H Titterton jr director buy | $132k 49,036 shares | +5% | - | |
| 35Weak | Lewis H Titterton jr director buy | $27k 10,000 shares | +1% | - | |
| 35Weak | Amit Kumar Chief Executive Officer buy | $8,250 3,000 shares | +0% | - | |
| 35Weak | Amit Kumar Chief Executive Officer buy | $14k 5,000 shares | +1% | - | |
| 26Weak | Lewis H Titterton jr director buy | $7,487 2,836 shares | +0% | +11% from low-50% from high | |
| 58Moderate | Amit Kumar Chief Executive Officer buy | $53k 21,000 shares | +3% | +5% from low-53% from high | |
| 31Weak | Arnold M Baskies director buy | $30k 10,000 shares | +8% | +27% from low-42% from high | |
| 44Moderate | Lewis H Titterton jr director buy | $31k 10,000 shares | +1% | +44% from low-23% from high | |
| 44Moderate | Amit Kumar Chief Executive Officer buy | $16k 5,000 shares | +1% | +48% from low-20% from high | |
| 30Weak | Arnold M Baskies director buy | $17k 5,000 shares | +4% | +62% from low-13% from high | |
| 39Weak | Lewis H Titterton jr director buy | $31k 10,000 shares | +1% | +47% from low-21% from high | |
| 44Moderate | Amit Kumar Chief Executive Officer buy | $16k 5,000 shares | +1% | +47% from low-21% from high | |
| 34Weak | Amit Kumar Chief Executive Officer buy | $29k 10,000 shares | +2% | +31% from low-30% from high | |
| 30Weak | Arnold M Baskies director buy | $14k 5,000 shares | +4% | - | |
| 30Weak | Lewis H Titterton jr director buy | $8,820 3,000 shares | +0% | - | |
| 30Weak | Lewis H Titterton jr director buy | $6,020 2,000 shares | +0% | - | |
| 30Weak | Lewis H Titterton jr director buy | $16k 6,000 shares | +1% | - | |
| 35Weak | Lewis H Titterton jr director buy | $26k 10,000 shares | +1% | - | |
| 43Moderate | Michael Catelani President, COO, & CFO buy | $20k 9,289 shares | +26% | - | |
| 53Moderate | Amit Kumar Chief Executive Officer buy | $96k 43,000 shares | +8% | - |
Transactions
Every row filed, 41 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Michael Catelani President, COO, & CFO | POpen-market purchase Common Stock | +5,500 | $2.84 | $16k | 50,000 | 13 d ago |
| Sep 24, 2026 | Arnold M Baskies director | POpen-market purchase Common Stock | +5,000 | $2.76 | $14k | 140,572 | 15 d ago |
| Sep 24, 2026 | Amit Kumar Chief Executive Officer | POpen-market purchase Common Stock | +7,000 | $2.78 | $19k | 672,000 | 15 d ago |
| Sep 23, 2026 | Lewis H Titterton jr director | POpen-market purchase Common Stock | +49,036 | $2.69 | $132k | 1,046,003 | 18 d ago |
| Sep 10, 2026 | Lewis H Titterton jr director | POpen-market purchase Common Stock | +10,000 | $2.73 | $27k | 996,967 | 29 d ago |
| Sep 10, 2026 | Amit Kumar Chief Executive Officer | POpen-market purchase Common Stock | +3,000 | $2.75 | $8,250 | 665,000 | 29 d ago |
| Sep 10, 2026 | Amit Kumar Chief Executive Officer | POpen-market purchase Common Stock | +5,000 | $2.76 | $14k | 662,000 | 32 d ago |
| Jun 16, 2026 | Lewis H Titterton jr director | POpen-market purchase Common Stock | +2,836 | $2.64 | $7,487 | 972,170 | Jun 17, 2026 |
| Jun 12, 2026 | Amit Kumar Chief Executive Officer | POpen-market purchase Common Stock | +21,000 | $2.50 | $53k | 630,812 | Jun 16, 2026 |
| Jan 28, 2026 | Arnold M Baskies director | POpen-market purchase Common Stock | +10,000 | $3.04 | $30k | 135,000 | Jan 29, 2026 |
| Jan 5, 2026 | Michael Catelani President, COO & CFO | AGrant or award Employee Stock Optionderivative | +175,000 | $0.00 | $0 | 175,000 | Jan 6, 2026 |
| Jan 5, 2026 | Lewis H Titterton jr director | AGrant or award Employee Stock Optionderivative | +25,000 | $0.00 | $0 | 25,000 | Jan 6, 2026 |
| Jan 5, 2026 | Amit Kumar Chief Executive Officer | AGrant or award Employee Stock Optionderivative | +350,000 | $0.00 | $0 | 350,000 | Jan 6, 2026 |
| Jan 5, 2026 | Emily Gottschalk director | AGrant or award Employee Stock Optionderivative | +25,000 | $0.00 | $0 | 25,000 | Jan 6, 2026 |
| Jan 5, 2026 | Arnold M Baskies director | AGrant or award Employee Stock Optionderivative | +25,000 | $0.00 | $0 | 25,000 | Jan 6, 2026 |
| Dec 15, 2025 | Lewis H Titterton jr director | MOption exercise Common Stock | +16,000 | $2.92 | $47k | 969,334 | Dec 16, 2025 |
| Dec 15, 2025 | Lewis H Titterton jr director | MOption exercise Employee Stock Optionderivative | -16,000 | $0.00 | $0 | 0 | Dec 16, 2025 |
| Oct 30, 2025 | Amit Kumar Chief Executive Officer | MOption exercise Common Stock | +200,000 | $2.92 | $584k | 779,925 | Oct 31, 2025 |
| Oct 30, 2025 | Amit Kumar Chief Executive Officer | FTax withholding Common Stock | -169,439 | $4.06 | $688k | 610,486 | Oct 31, 2025 |
| Oct 30, 2025 | Amit Kumar Chief Executive Officer | MOption exercise Employee Stock Option (Right to Buy)derivative | -200,000 | $0.00 | $0 | 0 | Oct 31, 2025 |
| Jul 31, 2025 | Lewis H Titterton jr director | POpen-market purchase Common Stock | +10,000 | $3.08 | $31k | 953,334 | Aug 4, 2025 |
| Jul 30, 2025 | Amit Kumar Chief Executive Officer | POpen-market purchase Common Stock | +5,000 | $3.16 | $16k | 579,925 | Jul 31, 2025 |
| Jul 18, 2025 | Arnold M Baskies director | POpen-market purchase Common Stock | +5,000 | $3.39 | $17k | 125,000 | Jul 21, 2025 |
| Jul 11, 2025 | Lewis H Titterton jr director | POpen-market purchase Common Stock | +10,000 | $3.14 | $31k | 943,334 | Jul 15, 2025 |
| Jul 11, 2025 | Amit Kumar Chief Executive Officer | POpen-market purchase Common Stock | +5,000 | $3.15 | $16k | 574,925 | Jul 14, 2025 |
| Jun 4, 2025 | Amit Kumar Chief Executive Officer | POpen-market purchase Common Stock | +10,000 | $2.85 | $29k | 569,925 | Jun 5, 2025 |
| Jan 28, 2025 | Arnold M Baskies director | POpen-market purchase Common Stock | +5,000 | $2.82 | $14k | 120,000 | Jan 29, 2025 |
| Jan 23, 2025 | Lewis H Titterton jr director | POpen-market purchase Common Stock | +2,000 | $2.91 | $5,820 | 932,334 | Jan 27, 2025 |
| Jan 24, 2025 | Lewis H Titterton jr director | POpen-market purchase Common Stock | +1,000 | $3.00 | $3,000 | 933,334 | Jan 27, 2025 |
| Jan 22, 2025 | Lewis H Titterton jr director | POpen-market purchase Common Stock | +2,000 | $3.01 | $6,020 | 930,334 | Jan 23, 2025 |
| Jan 21, 2025 | Lewis H Titterton jr director | POpen-market purchase Common Stock | +6,000 | $2.59 | $16k | 928,334 | Jan 22, 2025 |
| Jan 17, 2025 | Lewis H Titterton jr director | POpen-market purchase Common Stock | +10,000 | $2.57 | $26k | 922,334 | Jan 17, 2025 |
| Jan 15, 2025 | Michael Catelani President, COO, & CFO | POpen-market purchase Common Stock | +9,289 | $2.15 | $20k | 44,500 | Jan 15, 2025 |
| Jan 15, 2025 | Amit Kumar Chief Executive Officer | POpen-market purchase Common Stock | +43,000 | $2.23 | $96k | 559,925 | Jan 15, 2025 |
| Jan 2, 2025 | Arnold M Baskies director | AGrant or award Employee Stock Optionderivative | +25,000 | $0.00 | $0 | 25,000 | Jan 3, 2025 |
| Jan 2, 2025 | Michael Catelani President, COO & CFO | AGrant or award Employee Stock Optionderivative | +350,000 | $0.00 | $0 | 350,000 | Jan 3, 2025 |
| Jan 2, 2025 | Emily Gottschalk director | AGrant or award Employee Stock Optionderivative | +25,000 | $0.00 | $0 | 25,000 | Jan 3, 2025 |
| Jan 2, 2025 | Amit Kumar Chief Executive Officer | AGrant or award Employee Stock Optionderivative | +700,000 | $0.00 | $0 | 700,000 | Jan 3, 2025 |
| Jan 2, 2025 | Lewis H Titterton jr director | AGrant or award Employee Stock Optionderivative | +25,000 | $0.00 | $0 | 25,000 | Jan 3, 2025 |
| Oct 22, 2024 | Lewis H Titterton jr director | MOption exercise Common Stock | +16,000 | $2.58 | $41k | 912,334 | Oct 23, 2024 |
| Oct 22, 2024 | Lewis H Titterton jr director | MOption exercise Employee Stock Optionderivative | -16,000 | $0.00 | $0 | 0 | Oct 23, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Arnold M Baskiesdirector
- Michael CatelaniPresident, COO & CFO
- Emily Gottschalkdirector
- Amit KumarChief Executive Officer
- Lewis H Titterton jrdirector
Questions about ANIX
Answered from the filings on this page, as of the latest one.
Are insiders buying ANIX?
As of Sep 30, 2026, SEC Form 4 filings show 7 open-market buys worth $230k by 4 insiders and 0 open-market sells worth $0 by 0 insiders at Anixa Biosciences Inc in the last 90 days, net +$230k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade ANIX on the open market?
Michael Catelani (President, COO, & CFO) bought $16k of ANIX on Sep 30, 2026 and filed the Form 4 on Sep 30, 2026. InsiderTell scored 40 (moderate), with 4 insiders on the same side within 14 days.
How many insiders file Form 4 at Anixa Biosciences Inc?
5 people have filed a Form 4 at Anixa Biosciences Inc, among them Arnold M Baskies (director), Michael Catelani (President, COO & CFO), Emily Gottschalk (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.